Targets › ALDH1A1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Oct 2027.
Cytosolic dehydrogenase that catalyzes the NAD(+)-dependent irreversible oxidation of a wide range of aldehydes to their corresponding carboxylic acid. Functions downstream of retinol dehydrogenases and catalyzes the oxidation of retinaldehyde into retinoic acid, the second step in the oxidation of retinol/vitamin A into retinoic acid. (UniProt, P00352)
Open in Phaseline: the race on ALDH1A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nantes University Hospital | Post-Transplant Cyclophosphamide High-dose cyclophosphamide administered post-transplant for GVHD prophylaxis | ALDH1A1 | Phase 2 | Graft Versus Host Disease | Oct 2027 |
Graft Versus Host Disease (1)
small molecule (1)
Nantes University Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.